Besides, studies on 37,992 patient samples for assessment of HER2 expression levels demonstrated that HER2 protein overexpression was seen in 2.7% of samples predominantly in cancers of epithelial origin [80], while overexpression of HER2 protein was detected in 7–34% of gastric cancers [81]. This evidence concerns the gene ERBB2 and gastric cancer.